5.2
Impact Factor
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Corrigendum
Current Issue
Editorial
Erratum
Full Length Article
Full lenth article
Letter to Editor
Original Article
Research article
Retraction notice
Review
Review Article
SPECIAL ISSUE: ENVIRONMENTAL CHEMISTRY
5.3
Impact Factor
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Corrigendum
Current Issue
Editorial
Erratum
Full Length Article
Full lenth article
Letter to Editor
Original Article
Research article
Retraction notice
Review
Review Article
SPECIAL ISSUE: ENVIRONMENTAL CHEMISTRY
View/Download PDF

Translate this page into:

Original Article
10 (
1_suppl
); S1172-S1179
doi:
10.1016/j.arabjc.2013.02.011

Synthesis and evaluation of anti-inflammatory, antioxidant and antimicrobial activities of densely functionalized novel benzo [d] imidazolyl tetrahydropyridine carboxylates

University College of Technology, Osmania University, Hyderabad, AP 500007, India
Department of Pharmaceutical Chemistry, St. Peter’s Institute of Pharmaceutical Sciences, Vidyanagar, Hanamkonda, AP 506001, India

⁎Corresponding author. Tel.: +91 9866455957. ravindernathanisetti@gmail.com (Anisetti Ravindernath)

Disclaimer:
This article was originally published by Elsevier and was migrated to Scientific Scholar after the change of Publisher.

Peer review under responsibility of King Saud University.

Abstract

A series of novel benzo[d]imidazolyl tetrahydropyridine carboxylates 7a–n have been synthesized by one-pot multi-component reaction of (E)-5-(benzylidene amino)-1H-benzo[d]imidazole-2-thiol 3, 5-amino-2-mercapto-benzimidazole 4, aromatic aldehyde 5, and ethyl acetoacetate 6 in acetonitrile using ceric ammonium nitrate (CAN) as Lewis acid catalyst, and evaluated for their anti-inflammatory, antioxidant, antibacterial and antifungal activities. All tested compounds showed appreciable activity against the standard drugs.

Keywords

2-Mercapto-5-aminobenzimidazole
Benzo[d]imidazolyl tetrahydropyridine carboxylates
Ceric ammonium nitrate
Anti-inflammatory
Antioxidant
Antimicrobial activities
1

1 Introduction

Multi-component reactions (MCRs) have proved to be remarkably successful in generating products in a single synthetic operation (Eilbracht et al., 1999; Bora et al., 2003), and are of increasing importance in organic and medicinal chemistry (Kappe, 2000; Ugi, 2001; Ramon and Yus, 2005). In MCRs a high degree of molecule diversity can be introduced by variation of a single compound at a time. Considering that, rapidity and diversity are key factors in modern drug discovery. MCR strategies offer significant advantages over conventional linear-type synthesis, owing to their exceptional synthetic efficiency (Fayol and Zhu, 2005). MCRs contribute to the requirements of an environmentally friendly process by reducing the number of synthetic steps, energy consumption and waste production. Fused heterocycles have a wide variety of application in medicinal chemistry (Sperry and Wright, 2005; Ziegert et al., 2005). Despite several reports on fused heterocycles, there is a continuing demand for the development of new methods for synthesis of novel fused heterocycles due to their plethora of medicinal applications (Loughlin et al., 2004).

Benzimidazole a nitrogen containing heterocyclic provides an interesting building block for the synthesis of various biologically active compounds (Wright, 1951; Amari et al., 2002; Kozo et al., 2001), there are several classic examples of benzimidazole derivatives which possess useful pharmaceutical properties and they are marketed as commercial drugs. Benomyl and Fuberidazole are used as antifungal agents. Benzimidazole derivatives are also reported to possess analgesic (Sondhi et al., 2002), anti-helminthic (Hazelton et al., 1995; Labaw and Webb, 1981), anti-inflammatory (Ito et al., 1982), antimicrobial, anti-arthritic, and anti-HIV activities (Rao et al., 2002).

Several compounds consisting of reduced pyridine, like the 1,2,3,6-tetrahydropyridine 1 ring system shown in Fig. 1 are known to exhibit a variety of biological activities (Coutts and Casay, 1975; Ferles and Pliml, 1970). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 2 was recently found to be neurotoxic, causing persistent parkinsonism in humans and other animal species (Langston et al., 1983, 1984; Langston, 1985; Chiueh et al., 1985).

Biologically active 1,2,3,6-tetrahydropyridines as design templates.
Figure 1
Biologically active 1,2,3,6-tetrahydropyridines as design templates.

The pyridine motif is found in various therapeutic agents, including numerous antihistamines (Hisaki et al., 1987), antiseptic (Attia and Michael, 1982), anti-arrhythmic (Quintela et al., 1997), anti-rheumatic (Zhu et al., 2001) and other Pharmaceutical agents and natural products. It also plays a pivotal role in catalyzing both biological and chemical reactions (Roth and Kleeman, 1988). Highly functionalized pyridines, including aryl and heteroaryl-substituted derivatives, are widespread in the pharmaceutical and agrochemical sectors (Bashford et al., 2003; Raw and Taylor, 2004). Based on biological activity of tetrahydropyridines and benzimidazoles, it seemed that introduction of benzimidazole, tetrahydropyridine rings in a single molecular frame work may enhance the pharmacological activity of these compounds. As a sequel to our research on the design and synthesis of biologically active and pharmacologically important new heterocycles (Ravindernath and Srinivas Reddy, 2012a,b,c), it was thought worthwhile to synthesize the novel title compounds 7a–n and to have them evaluated for their anti-inflammatory, antioxidant, antimicrobial activities.

2

2 Material and methods

2.1

2.1 Material and reagents

All the melting points were determined on a Cintex melting point apparatus and are uncorrected. Analytical TLC was performed on Merck precoated 60 F254 silica gel plates. Visualization was done by exposure to iodine vapor. Column chromatography was conducted by using silica gel with ethyl acetate: n-hexane solvent system as elute. IR spectra (KBr pellet) were recorded on a Perkin–Elmer BX series FT-IR spectrometer. 1H NMR spectra were recorded on a Varian Gemini 300 MHz spectrometer. 13C NMR spectra were recorded on a Bruker 75 MHz spectrometer. Chemical shift values are given in ppm (δ) with tetramethyl silane as an internal standard. Mass spectral measurements were carried out by the EI method on a Joel JMC-300 spectrometer at 70 eV. Elemental analyses were performed on a Carlo Erba 106 and Perkin–Elmer model 240 analyzers.

2.2

2.2 Synthesis of methyl-2,6-diphenyl-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2-sulfanyl-1H-benzo[d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7a–n)

A mixture of (E)-5-(benzylidene amino)-1H-benzo[d]imidazole-2-thiole 3 (0.01 mmol), 5-amino-2-mercaptobenzimidazole 4 (0.01 mmol), aromatic aldehyde 5 (0.01 mmol) and ethyl acetoacetate 6 (0.01 mmol) in CH3CN (15 ml) with 10 mol% CAN was stirred at room temperature for 6 h. After completion of the reaction (monitored by TLC), reaction mixture was poured into crushed ice. The separated solid was filtered and purified by column chromatography using ethyl acetate and n-hexane (6:4) elutant.

2.4.1

2.4.1 Methyl 2,6-diphenyl-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2-sulfanyl-1H-benzo [d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7a)

Yield 81%, m.p. 172–174 °C. IR (KBr): 3360, 3042, 1657, 1580, 1510, 940 cm−1. 1H NMR (300 MHz, CDCl3): δ = 0.91 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.75 (dd, J = 15.2 and 2.4 Hz, 1H, H-5a), 2.85 (dd, J = 15.2 and 5.7 Hz, 1H, H-5b), 4.01(q, 2H, OCH2CH3, J = 7.2 Hz), 4.51 (s, 2H, 2SH), 5.11 (d, J = 4 Hz, 1H, H-6), 6.11 (s, 1H, Ar-CH), 7.33–7.75 (m, 16H, ArH), 10.11 (s, 1H, NH, D2O exchangeable), 10.61 (s, 2H, 2NH, D2O exchangeable). 13C NMR (75 MHz, CDCl3) δ: 14.26, 36.29, 39.26, 53.25, 61.51, 101.22, 102.41, 104.37, 116.20, 116.36, 116.48, 118.20, 127.20, 127.25, 127.56, 127.63, 127.70, 127.80, 128.22, 128.32, 128.34, 128.38, 128.42, 128.70, 134.64, 138.28, 139.50, 139.62, 141.27, 141.41, 148.32, 167.42, 168.42, 168.44. EI-MS m/z: 618 [M+]. Anal. Cald. For (C34H30N6O2S2) (%): C, 66.00; H, 4.89; N, 13.58. Found: C, 66.06; H, 4.81; N, 13.51.

2.4.2

2.4.2 Methyl 6-(2-hydroxyphenyl)-2-phenyl-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2- sulfanyl-1H-benzo[d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7b)

Yield 84%, m.p. 163–165 °C: IR (KBr): 3450, 3352, 3022, 1670, 1573, 1525, 921 cm−1. 1H NMR (300 MHz, CDCl3): δ = 0.92 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.65 (dd, J = 15.2 and 2.4 Hz, 1H, H-5a), 2.78 (dd, J = 15.2 and 5.7 Hz, 1H, H-5b), 4.01 (q, 2H, OCH2CH3, J = 7.2 Hz), 4.48 (s, 2H, 2SH), 5.14 (d, J = 4 Hz, 1H, H-6), 6.12 (s, 1H, Ar-CH),7.41–7.88 (m, 15H, ArH), 8.1 (bs, 1H, OH, D2O exchangeable), 10.21 (s, 1H, NH, D2O exchangeable), 10.52 (s, 2H, 2NH, D2O exchangeable). 13C NMR (75 MHz, CDCl3) δ: 14.10, 33.25, 36.52, 53.22, 61.52, 101.22, 102.42, 104.45, 115.82, 116.20, 116.22, 116.29, 118.22, 121.22, 125.52, 127.20, 127.38, 127.70, 127.75, 128.24, 128.26, 128.32, 128.34, 128.72, 134.62, 138.30, 139.56, 139.70, 141.22, 148.32, 155.24, 167.43, 168.38, 168.42. EI-MS m/z: 634 [M+]. Anal. Cald. For (C34H30N6O3S2) (%): C, 64.33; H, 4.76; N, 13.24. Found: C, 64.05; H, 4.72; N, 13.27.

2.4.3

2.4.3 Methyl 6-(2-chlorophenyl)-2-phenyl-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2- sulfanyl-1H-benzo[d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7c)

Yield 86%, m.p. 171–173 °C. IR (KBr): 3362, 3024, 1660, 1543, 1514, 921 cm−1. 1H NMR (300 MHz, CDCl3): δ = 0.93 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.70 (dd, J = 15.2 and 2.4 Hz, 1H, H-5a), 2.83 (dd, J = 15.2 and 5.7 Hz, 1H, H-5b), 4.12(q, 2H, OCH2CH3, J = 7.2 Hz), 4.31 (s, 2H, 2SH), 5.11 (d, J = 4 Hz, 1H, H-6), 6.10 (s, 1H, Ar-CH), 7.10–8.00 (m, 15H, ArH), 10.02 (s, 1H, NH, D2O exchangeable), 10.48 (s, 2H, 2NH, D2O exchangeable). 13C NMR (75 MHz, CDCl3) δ: 14.29, 34.50, 35.72, 53.22, 61.50, 101.20, 102.35, 104.41, 116.18, 116.21, 116.28, 118.25, 126.42, 127.23, 127.70, 127.76, 128.21, 128.31, 128.36, 128.46, 128.61, 128.73, 129.52, 133.40, 134.62, 138.31, 138.52, 139.52, 139.62, 141.24, 148.34, 167.40, 168.41, 168.42. EI-MS m/z: 652 [M+]. Anal. Cald. For (C34H29N6O2S2Cl) (%): C, 62.52; H, 4.47; N, 12.87. Found: C, 62.50; H, 4.50; N, 12.82.

2.4.4

2.4.4 Methyl 6-(4-chlorophenyl)-2-phenyl-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2- sulfanyl-1H-benzo[d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7d)

Yield 79%, m.p. 178–180 °C. IR (KBr): 3362, 3033, 1660, 1569, 1532, 946 cm−1. 1H NMR (300 MHz, CDCl3): δ = 0.89 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.75 (dd, J = 15.2 and 2.4 Hz, 1H, H-5a), 2.89 (dd, J = 15.2 and 5.7 Hz, 1H, H-5b), 4.10(q, 2H, OCH2CH3, J = 7.2 Hz), 4.20 (s, 2H, 2SH), 5.14 (d, J = 4 Hz, 1H, H-6), 6.10 (s, 1H, Ar-CH), 7.00–8.10 (m, 15H, ArH), 10.11 (bs, 1H, NH, D2O exchangeable), 10.50 (s, 1H, 2NH, D2Oexchangeable). 13C NMR (75 MHz, CDCl3) δ: 14.02, 36.22, 39.27, 53.62, 61.51, 101.25, 102.45, 104.42, 116.20, 116.22, 116.61, 118.22, 127.21, 127.72, 127.74, 128.01, 128.22, 128.32, 128.36, 128.45, 128.61, 128.74, 128.81, 132.42, 134.61, 138.29, 139.26, 139.61, 139.92, 141.01, 148.32, 167.42, 168.01, 168.45. EI-MS m/z: 652 [M+]. Anal. Cald. For (C34H29N6O2S2Cl) (%): C, 62.52; H, 4.47; N, 12.87. Found: C, 62.56; H, 4.49; N, 12.91.

2.4.5

2.4.5 Methyl 6-(2-bromophenyl)-2-phenyl-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2- sulfanyl-1H-benzo[d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7e)

Yield 82%, m.p. 160–162 °C. IR (KBr): 3355, 3038, 1672, 1574, 1531, 933 cm−1. 1H NMR (300 MHz, CDCl3): δ = 0.94 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.68 (dd, J = 15.2 and 2.4 Hz, 1H, H-5a), 2.78 (dd, J = 15.2 and 5.7 Hz, 1H, H-5b), 4.10(q, 2H, OCH2CH3, J = 7.2 Hz), 4.40 (s, 2H, 2SH), 5.23 (d, J = 4 Hz, 1H, H-6), 6.09 (s, 1H, Ar-CH), 7.04–7.83 (m, 15H, ArH), 10.14 (s, 1H, NH, D2O exchangeable), 10.50 (s, 2H, 2NH, D2O exchangeable). 13C NMR (75 MHz, CDCl3) δ: 14.45, 35.42, 35.90, 61.53, 53.27, 101.25, 102.41, 104.26, 116.22, 116.25, 116.66, 118.28, 122.70, 127.21, 127.30, 127.70, 127.75, 128.32, 128.36, 128.64, 128.74, 129.41, 130.22, 132.30, 134.61, 138.21, 139.58, 139.62, 140.31, 141.20, 148.33, 167.41, 168.41, 168.44. EI-MS m/z: 696 [M+]. Anal. Cald. For (C34H29N6O2S2Br) (%): C, 58.53; H, 4.19; N, 12.05. Found: C, 58.53; H, 4.19; N, 12.07.

2.4.6

2.4.6 Methyl 6-(4-bromophenyl)-2-phenyl-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2- sulfanyl-1H-benzo[d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7f)

Yield 86%, m.p. 166–168 °C. IR (KBr): 3364, 3042, 1675, 1568, 1531, 937 cm−1.1H NMR (300 MHz, CDCl3): δ = 0.89 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.70 (dd, J = 15.2 and 2.4 Hz, 1H, H-5a), 2.79 (dd, J = 15.2 and 5.7 Hz, 1H, H-5b), 4.20(q, 2H, OCH2CH3, J = 7.2 Hz), 4.43 (s, 2H, 2SH), 5.01 (d, J = 4 Hz, 1H, H-6), 6.11 (s, 1H, Ar-CH), 7.12–7.77 (m, 15H, ArH), 10.00 (s, 1H, NH, D2O exchangeable), 10.48 (s, 2H, 2NH, D2O exchangeable).13C NMR (75 MHz, CDCl3) δ: 14.01, 36.21, 39.22, 53.21, 61.50, 101.22, 102.41, 104.41, 116.21, 116.32, 116.60, 118.20, 121.01, 127.26, 127.72, 127.75, 128.01, 128.25, 128.34, 128.44, 128.70, 128.74, 131.20, 131.22, 134.42, 138.24, 139.52, 139.61, 140.40, 141.23, 148.33, 167.41, 168.40, 168.42. EI-MS m/z: 696 [M+]. Anal. Cald. For (C34H29N6O2S2Br) (%): C, 58.53; H, 4.19; N, 12.05. Found: C, 58.50; H, 4.22; N, 12.01.

2.4.7

2.4.7 Methyl 6-(4-methylphenyl)-2-phenyl-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2- sulfanyl-1H-benzo[d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7g)

Yield 86%, m.p. 170–172 °C. IR (KBr): 3355, 3032, 1657, 1575, 1532, 943 cm−1. 1H NMR (300 MHz, CDCl3): δ = 0.90 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.59 (dd, J = 15.2 and 2.4 Hz, 1H, H-5a), 2.68 (s, 3H, ArCH3), 2.80 (dd, J = 15.2 and 5.7 Hz, 1H, H-5b), 4.01(q, 2H, OCH2CH3, J = 7.2 Hz), 4.68 (s, 2H, 2SH), 5.21 (d, J = 4 Hz, 1H, H-6), 6.10 (s, 1H, Ar-CH), 7.15–7.64 (m, 15H, ArH), 10.21 (s, 1H, NH, D2O exchangeable), 10.43 (s, 2H, 2NH, D2O exchangeable). 13C NMR (75 MHz, CDCl3) δ: 14.45, 21.54, 36.26, 39.22, 53.20, 61.52, 101.25, 102.41, 104.42, 116.21, 116.23, 116.32, 118.22, 126.10, 126.50, 127.21, 127.70, 127.75, 128.22, 128.32, 128.35, 128.61, 128.63, 128.70, 134.62, 136.52, 138.31, 138.41, 139.52, 139.61, 141.22, 148.32, 167.48. 168.41, 168.42, EI-MS m/z: 632 [M+]. Anal. Cald. For (C35H32N6O2S2) (%): C, 66.43; H, 5.10; N, 13.28. Found: C, 66.48; H, 5.08; N, 13.30.

2.4.8

2.4.8 Methyl 6-(4-methoxyphenyl)-2-phenyl-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2-sulfanyl-1H-benzo[d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7h)

Yield 86%, m.p. 175–177 °C. IR (KBr): 3339, 3028, 1660, 1563, 1522, 935 cm−1.1H NMR (300 MHz, CDCl3): δ = 0.88 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.69 (dd, 1H, CH, J = 15.2, 2.4 Hz), 2.80 (dd, 1H, CH, J = 15.2, 5.7 Hz), 3.62 (s, 3H, OCH3), 4.08 (q, 2H, OCH2CH3, J = 7.2 Hz), 4.20 (s, 2H, 2SH), 5.04 (d, J = 4 Hz, 1H, H-6), 6.11 (s, 1H, Ar-CH), 7.14–7.93 (m, 15H, ArH), 10.08 (s, 1H, NH, D2O exchangeable), 10.51 (s, 2H, 2NH, D2O exchangeable). 13C NMR (75 MHz, CDCl3) δ: 14.01, 36.25, 39.26, 53.21, 61.52, 62.50, 101.62, 102.40, 104.42, 114.21, 114.22, 116.24, 116.33, 116.62, 118.22, 127.18, 127.42, 127.78, 127.70, 127.71, 128.22, 128.32, 128.70, 128.72, 133.62, 134.61, 138.32, 139.52, 139.64, 141.32, 148.32, 158.71, 167.41, 168.01, 168.42. EI-MS m/z: 648 [M+]. Anal. Cald. For (C35H32N6O3S2) (%): C, 64.79; H, 4.97; N, 12.95. Found: C, 64.72; H, 4.96; N, 12.98.

2.4.9

2.4.9 Methyl 6-(2-methoxyphenyl)-2-phenyl-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2-sulfanyl-1H-benzo[d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7i)

Yield 82%, m.p. 181–183 °C. IR (KBr):3341, 3039, 1675, 1573, 1527, 929 cm−1. 1H NMR (300 MHz, CDCl3): δ = 0.80 (t, 3H, OCH2CH3, J = 7.2 Hz), 22.60 (dd, J = 15.2 and 2.4 Hz, 1H, H-5a), 2.83 (dd, J = 15.2 and 5.7 Hz, 1H, H-5b), 3.62(s,3H, OCH3), 4.06(q, 2H, OCH2CH3, J = 7.2 Hz), 4.26 (s, 2H, 2SH), 5.08 (d, J = 4 Hz, 1H, H-6), 6.10 (s, 1H, Ar-CH), 7.03–7.82 (m, 15H, ArH), 10.16 (s, 1H, NH, D2O exchangeable), 10.40 (s, 2H, 2NH, D2O exchangeable). 13C NMR (75 MHz, CDCl3) δ: 14.02, 33.31, 36.54, 53.26, 61.20, 61.52, 101.25, 102.40, 104.41,112.22, 116.20, 116.21, 116.62, 118.20, 120.60, 124.28, 127.20, 127.21, 127.70, 127.75, 128.21, 128.23, 128.32, 128.34, 128.74, 134.61, 138.21, 139.52, 139.61, 141.22, 148.31, 157.32, 167.01, 168.40, 168.42. EI-MS m/z: 648 [M+]. Anal. Cald. For (C35H32N6O3S2) (%): C, 64.79; H, 4.97; N, 12.95. Found: C, 64.83; H, 4.95; N, 12.91.

2.4.10

2.4.10 Methyl 6-(4-nitrophenyl)-2-phenyl-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2- sulfanyl-1H-benzo[d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7j)

Yield 92%, m.p. 179–181 °C. IR (KBr):3365, 3037, 1660, 1523, 1545, 1560, 1356, 923 cm−1. 1H NMR (300 MHz, CDCl3): δ = 0.93 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.60 (dd, J = 15.2 and 2.4 Hz, 1H, H-5a), 2.83 (dd, J = 15.2 and 5.7 Hz, 1H, H-5b), 4.03(q, 2H, OCH2CH3, J = 7.2 Hz), 4.58 (s, 2H, 2SH), 5.10 (d, J = 4 Hz, 1H, H-6), 6.09 (s, 1H, Ar-CH), 6.98–7.69 (m, 14H, ArH), 10.00 (s, 1H, NH, D2O exchangeable), 10.53 (s, 2H, 2NH, D2O exchangeable). 13C NMR (75 MHz, CDCl3) δ: 14.40, 36.22, 39.20, 53.20, 61.52, 101.24, 102.42, 104.42, 116.20, 116.22, 116.24, 118.21, 123.52, 123.55, 124.22, 124.24, 127.28, 127.70, 127.75, 128.22, 128.35, 128.38, 128.71, 134.62, 138.22, 139.54, 139.67, 141.20, 146.43, 147.51, 148.32, 167.42, 168.42, 168.44. EI-MS m/z: 663 [M+]. Anal. Cald. For (C34H29N7O4S2) (%): C, 61.52; H, 4.40; N, 14.77. Found: C, 61.48; H, 4.45; N, 14.79.

2.4.11

2.4.11 Methyl 2-(2-chlorophenyl)-6-(2-hydroxyphenyl)-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2-sulfanyl-1H-benzo[d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7k)

Yield 88%, m.p. 168–170 °C. IR (KBr): 3462, 3333, 3025, 1680, 1564, 1532, 938 cm−1. 1H NMR (300 MHz, CDCl3): δ = 0.90 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.60 (dd, J = 15.2 and 2.4 Hz, 1H, H-5a), 2.80 (dd, J = 15.2 and 5.7 Hz, 1H, H-5b), 4.08 (q, 2H, OCH2CH3, J = 7.2 Hz), 4.58 (s, 2H, 2SH), 5.21 (d, J = 4 Hz, 1H, H-6), 6.11 (s, 1H, Ar-CH), 7.01–7.88 (m, 14H, ArH), 8.43(s, 1H, OH, D2O exchangeable), 10.18 (s, 1H, NH, D2O exchangeable), 10.51 (s, 2H, 2NH, D2O exchangeable). 13C NMR (75 MHz, CDCl3) δ: 14.01, 34.76, 34.12, 47.43, 61.54, 101.41, 102.21, 104.44, 115.52, 116.21, 116.22, 116.63, 117.45, 118.23, 121.01, 126.41, 128.22, 128.43, 128.62, 128.64, 128.73, 129.01, 29.11, 133.42, 134.09, 138.54, 139.44, 139.52, 141.23, 148.34, 155.20, 167.42, 168.01, 168.48. EI-MS m/z: 668 [M+]. Anal. Cald. For (C34H29N6O3S2Cl) (%): C, 61.02; H, 4.37; N, 12.56. Found: C, 61.06; H, 4.39; N, 12.59.

2.4.12

2.4.12 Methyl 2-(2-bromophenyl)-6-(2-hydroxyphenyl)-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2-sulfanyl-1H-benzo[d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7l)

Yield 82%, m.p. 176–178 °C. IR (KBr): 3453, 3352, 3043, 1675, 1567, 1529, 912 cm−1. 1H NMR (300 MHz, CDCl3): δ = 0.98 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.70 (dd, J = 15.2 and 2.4 Hz, 1H, H-5a), 2.85 (dd, J = 15.2 and, 5.7 Hz, 1H, H-5b), 4.10 (q, 2H, OCH2CH3, J = 7.2 Hz), 4.50 (s, 2H, 2SH), 5.30 (d, J = 4 Hz, 1H, H-6), 6.11 (s, 1H, Ar-CH), 7.00–7.79 (m, 14H, ArH), 10.20 (s, 1H, NH, D2O exchangeable), 10.44 (s, 2H, 2NH, D2O exchangeable). 13C NMR (75 MHz, CDCl3) δ: 14.44, 35.41, 35.52, 47.44, 61.51, 101.22, 102.38, 104.41, 115.52, 116.21, 116.24, 116.26, 117.41, 118.20, 121.20, 122.70, 127.36, 128.20, 128.61, 128.70, 129.45, 129.50, 130.23, 132.34, 134.61, 139.50, 139.62, 140.32, 141.21, 148.71, 155.20, 167.41, 168.38, 168.41. EI-MS m/z: 712 [M+]. Anal.Cald. For (C34H29N6O3S2Br) (%): C, 57.22; H, 4.10; N, 11.78. Found: C, 57.18; H, 4.09; N, 11.81.

2.4.13

2.4.13 Methyl 6-(2-chlorophenyl)-2-(2-hydroxyphenyl)-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2-sulfanyl-1H-benzo[d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7m)

Yield 86%, m.p. 180–182 °C. IR (KBr): 3471, 3340, 3033, 1665, 1568, 1535, 922 cm−1. 1H NMR (300 MHz, CDCl3): δ = 0.93 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.70 (dd, J = 15.2 and 2.4 Hz, 1H, H-5a), 2.83(dd, J = 15.2 and 5.7 Hz, 1H, H-5b), 4.12(q, 2H, OCH2CH3, J = 7.2 Hz), 4.31 (s, 2H, 2SH), 5.11 (d, J = 4 Hz, 1H, H-6), 6.09 (s, 1H, Ar-CH), 7.10–8.00 (m, 14H, ArH), 8.88 (s, 1H, OH, D2O exchangeable), 10.02 (s, 1H, NH, D2O exchangeable), 10.48 (s, 2H, 2NH, D2O exchangeable). 13C NMR (75 MHz, CDCl3) δ: 14.40, 33.01, 36.53, 48.52, 61.52, 101.22, 102.42, 104.44, 115.53, 116.22, 116.25, 116.61, 118.61, 121.26, 125.56, 126.41, 127.32, 128.22, 128.24, 128.41, 128.68, 128.70, 129.50, 133.41, 134.62, 137.42, 139.56, 139.61, 141.24, 148.32, 155.20, 167.42, 168.39, 168.42. EI-MS m/z: 686 [M+]. Anal. Cald. For (C34H29N6O3S2Cl) (%): C, 61.02; H, 4.37; N, 12.56. Found: C, 61.06; H, 4.33; N, 12.53.

2.4.14

2.4.14 Methyl 6-(2-chlorophenyl)-2-(2-methoxyphenyl)-1-(2-sulfanyl-1H-benzo[d]imidazol-5-yl)-4-[(2-sulfanyl-1H-benzo[d]imidazol-6-yl)amino]-1,2,5,6-tetrahydro-3-pyridinecarboxylate (7n)

Yield 79%, m.p. 176–178 °C. IR (KBr): 3348, 3022, 1660, 1561, 1513, 937 cm−1. 1H NMR (300 MHz, CDCl3): δ = 0.89 (t, 3H, OCH2CH3, J = 7.2 Hz), 2.75 (dd, J = 15.2 and 2.4 Hz, 1H, H-5a), 2.89 (dd, J = 15.2 and 5.7 Hz, 1H, H-5b), 3.63(s, 3H, OCH3), 4.10 (q, 2H, OCH2CH3, J = 7.2 Hz), 4.20 (s, 2H, 2SH), 5.14 (d, J = 4 Hz, 1H, H-6), 6.10 (s, 1H, Ar-CH), 7.00–8.10 (m, 14H, ArH), 10.11 (s, 1H, NH, D20 exchangeable), 10.50 (s, 2H, 2NH, D2O exchangeable). 13C NMR (75 MHz, CDCl3) δ: 14.03, 33.32, 36.52, 48.53, 61.51, 62.25, 101.22, 102.41, 104.39, 112.22, 116.20, 116.22, 116.62, 118.20, 120.63, 124.21, 126.20, 127.25, 128.21, 128.26, 128.28, 128.71, 128.83, 129.12, 133.41, 134.63, 137.44, 139.50, 139.62, 141.27, 148.31, 157.32, 167.42, 168.42, 168.44. EI-MS m/z: 668 [M+]. Anal. Cald. For (C35H31N6O3S2Cl) (%): C, 61.53; H, 4.57; N, 12.30. Found: C, 61.50; H, 4.53; N, 12.28.

3

3 Biological activity

3.1

3.1 Anti-inflammatory activity

Albino rats weighing 150–180 g were used in this method. They were kept in the animal house under standard conditions of light and dark (12 h) with free access to food and libitum water. The rats were randomly divided into groups, of six rats each. The group VI, six rats are kept as a control and the group VII received the standard drug Diclofenac sodium (at a dose of 10 mg/kg body weight PO). All the test compounds 7a–n were dissolved in 0.1% solution of Tween 80 and given 60 min before the commencement of the study. Then 0.1 ml of 1% w/v carrageenan solution in normal saline was injected into the sub planter region of the left hind paw under light ether anesthesia, 1hr after oral administration (PO) of the test compound. The difference between the paw volumes of treated animals was compared with that of the control group and the mean edema volume was calculated. Percentage inhibition was calculated as per the formula, %inhibition = [(Vo − Vt)/Vo] × 100, where Vo = volume of the paw control at time t, Vt = volume of the paw of drug treated at time t. The paw volume of each rat was measured immediately by mercury plethysmometer and re-measured again at 1, 2, 3 and 4 h after administration of Tween 80. The edema was expressed as an increase in the volume of the paw edema.

The anti inflammatory activities of the newly synthesized compounds 7a–n (I–XIV groups) were evaluated by applying carrageenan-induced paw edema test in rats (Winter et al., 1962), using Diclofenac sodium as a reference drug for comparison. Results were expressed as Mean ± S.E. Difference between vehicle control and treatment groups was tested using one way Analysis of Variance (ANOVA) followed by the Dunnett’s test and least significant difference (L.S.D). Methods of statistical analysis were done according to (Armitage, 1971) .The anti inflammatory activity (Table 3) indicated that all the tested compounds in 60 min prior to carrageenan injection at a dose of 10 mg/kg weight caused significant inhibition of paw edema response.

3.2

3.2 Antioxidant activity

To 0.1 ml of test compound (at different concentrations), 1.5 ml of methanol and 0.5 ml of DPPH solution were added, mixed thoroughly and absorbance (OD) was read at 517 nm against the blank. The% reduction of free radical concentration (OD) with different concentrations of test compounds was calculated and was compared with standard, ascorbic acid. The results were expressed as IC50 values (the concentration of test required to scavenge 50% free radicals).

3.3

3.3 Antibacterial activity

The ready-made nutrient broth medium (Himedia, 24 g) was suspended in distilled water (100 ml) and heated until it dissolved completely. The medium and test tubes were autoclaved at a pressure of 15 lb/inch2 for 20 min. A set of sterilized test tubes with nutrient broth medium was capped with cotton plugs. The test compound was dissolved in acetone and a concentration of 100 μg/ml of the compound was added in the first test tube, which was serially diluted. A fixed volume of 0.5 ml of overnight culture was added in all the test tubes and incubated at 37 °C for 24 h. After 24 h these tubes were measured for turbidity and the data are presented in Table 1.

Table 1 Anti-inflammatory activity of compounds (7a–n).
Groupa 1 hr 2 hr 3 hr 4 hr
Volume of edema (mL)b
7a 0.78 ± 0.022 1.45 ± 0.057 0.5 ± 0.027a 0.08 ± 0.003 a
7b 0.68 ± 0.043 1.45 ± 0.040 0.68 ± 0.022b 0.26 ± 0.216 a
7c 0.88 ± 0.0286 1.8 ± 0.058 0.516 ± 0.033 a 0.18 ± 0.016 a
7d 0.7 ± 0.0258 1.7 ± 0.067 0.76 ± 0.048c 0.18 ± 0.019 b
7e 0.55 ± 0.0389 1.583 ± 0.045 0.616 ± 0.0315 a 0.3 ± 0.023 a
7f 0.65 ± 0.035 1.36 ± 0.030 0.5 ± 0.021 a 0.18 ± 0.02 a
7g 0.78 ± 0.30 1.6 ± 0.0812 0.7 ± 0.0210 b 0.43 ± 0.024 a
7h 0.72 ± 0.018 1.5 ± 0.088 0.3 ± 0.028 a 0.07 ± 0.002 a
7i 0.64 ± 0.011 1.4 ± 0.038 0.31 ± 0.024 a 0.06 ± 0.002 a
7j 0.80 ± 0.026 1.76 ± 0.068 0.5 ± 0.027 a 0.1 ± 0.003 a
7k 0.76 ± 0.019 1.6 ± 0.808 0.34 ± 0.026 a 0.09 ± 0.002 a
7l 0.69 ± 0.010 1.7 ± 0.065 0.30 ± 0.024 a 0.08 ± 0.002 a
7m 0.73 ± 0.018 1.7 ± 0.07 0.5 ± 0.029 a 0.1 ± 0.002 a
7n 0.82 ± 0.030 1.76 ± 0.07 0.58 ± 0.03 a 0.1 ± 0.002 a
Control 0.90 ± 0.04 1.60 ± 0.018 2.38 ± 0.02 3.25 ± 0.03
Diclofenac sodium 0.95 ± 0.03 1.72 ± 0.03 0.60 ± 0.03a 0.60 ± 0.02a

Values are expressed as mean ± S.E (Number of animals N = 6 rats).

Statistically significant compared to respective control values.

***P < 0.001 (Dunnett’s test).
**P < 0.01 (Dunnett’s test).
*P < 0.05 (Dunnett’s test).

3.4

3.4 Antifungal activity

The ready-made potato dextrose agar medium (Himedia, 39 g) was suspended in distilled water (100 ml) and heated until it dissolved completely. The medium was poured into sterile Petri dishes under aseptic conditions in a laminar flow chamber. When the medium in plates was solidified, 0.5 ml of culture (one week old) of fungal spore suspension was inoculated and uniformly spread over the agar surface with a sterile L-shaped rod. Solutions were prepared by dissolving the test compound in acetone. Agar inoculation cups were scooped out with a 6 mm sterile cork borer and the lids of the dishes were replaced. To each cup, different concentrations of test solution were added. Controls were maintained with acetone and fluconazole. The test and the controls were kept at room temperature for 72–96 h. Inhibition zones were measured and the diameter was calculated in millimeters. Three to four replicates were maintained for each treatment. The results are summarized in Table 4.

4

4 Results and discussion

4.1

4.1 Chemistry

In the current investigation benzo[d]imidazolyl tetrahydropyridine carboxylates (7a–n) have been prepared from a mixture of (E)-5-(benzylidene amino)-1H-benzo[d] imidazole-2-thiol 3, 5-amino-2-mercapto-benzimidazole 4, aromatic aldehyde 5 and ethyl acetoacetate 6 in acetonitrile (15 ml) with 10 mol% of CAN at room temperature in good yields (79–92%) (Scheme 1). The structures of all the newly synthesized compounds have been established on their elemental analysis IR, 1H NMR, 13C NMR and MS spectral data.

Synthesis of novel benzo[d]imidazolyl tetrahydropyridine carboxylates. Reagents and conditions: (a) CH3CN, 10 mol% CAN, Stirring, r.t, 4 h.
Scheme 1
Synthesis of novel benzo[d]imidazolyl tetrahydropyridine carboxylates. Reagents and conditions: (a) CH3CN, 10 mol% CAN, Stirring, r.t, 4 h.

In the IR spectra of 7a–n a strong absorption band appeared at 1657 cm−1 corresponding to the carbonyl functional group. 1H NMR spectra of 7 showed signals as doublet of doublet at δ 2.75, 2.85 due to CH2, doublet at δ 5.11 due to Ar-CH and singlet at δ 6.11 due to Ar-CH which well support the structure. In the 13C NMR spectra, the prominent signals corresponding to the tetrahydropyridine ring observed nearly at δ 47.69, 56.22, 61.73, 101.43 and 132.72 are the further evidence of the structure. The mass spectra of 7a exhibited a molecular ion peak (M+) 681 m/z in conformity with the product formation.

4.2

4.2 Anti- inflammatory activity

The anti-inflammatory activity was evaluated by the Carrageenan-induced paw edema test in rats (Winter et al., 1962). The investigation of anti-inflammatory activity screening data revealed that almost all the tested compounds showed interesting activity, however with a degree of variation. A few among them have significant acute as well as residual anti-inflammatory activity. Compounds of groups 7a, 7c, 7e, 7f, 7h, 7i, 7j, 7l, 7m and 7n showed significantly decreased paw edema during 3, and 4 h after drug administration, 7b and 7g showed moderately decreased paw edema during 3 h of administration and after drug administration, but showed highly significant decreased paw edema during 4 h. This may be due to the presence of electron donating group as substituent. 7d Showed mild decreased paw edema during 3 h after drug administration but moderate decreased paw edema during 4 h. The results are illustrated in Table 1.

4.3

4.3 Antioxidant activity

For the evaluation of antioxidant activity, we have used a stable free radical α,α -diphenyl-β-picryl hydrazyl (DPPH), at the concentration of 0.2 mM in methanol (Ranjit et al., 2010). The antioxidant DPPH free radical scavenging activity of all the synthesized compounds 7a–n performed using DPPH method is shown in Table 2. All the synthesized compounds produced a concentration dependant scavenging of the free radical, DPPH. The IC50 values of all the compounds 7a–e were found between 3.8 μM and 40 μM, with antioxidant activity. Compounds 7b, 7i and 7j possessing 2-hydroxy, 2-methoxy and 4-nitro groups as substitutions respectively on the benzene ring showed better activity against DPPH free radicals. Both the electron donating and electron withdrawing groups present as substituent enhanced the antioxidant activity. These results suggest that all the compounds exhibited remarkable antioxidant activity than the standard ascorbic acid.

Table 2 Antioxidant activity of compounds (7a–n).
Compound Ar Ar′ IC50 (μM)
7a C6H5 C6H5 40.0
7b C6H5 2-OHC6H4 6.6
7c C6H5 2-ClC6H4 31.0
7d C6H5 4-ClC6H4 15.0
7e C6H5 2-BrC6H4 30.0
7f C6H5 4-BrC6H4 26.0
7g C6H5 4-CH3C6H4 17.0
7h C6H5 4-OCH3C6H4 22.0
7i C6H5 2-OCH3C6H4 4.2
7j C6H5 4-NO2C6H4 3.8
7k 2-OHC6H4 2-ClC6H4 28.0
7l 2-OHC6H4 2-BrC6H4 16.0
7m 2-ClC6H4 2-OHC6H4 22.0
7n 2-ClC6H4 2-OCH3C6H4 10.0
Ascorbic acid 8.64

4.4

4.4 Antibacterial activity

The newly synthesized compounds 7a–n were tested for their in vitro antibacterial activity against gram-positive bacteria viz., Bacillus cereus (ATCC 6633), Bacillus subtilis (ATCC 12711) and Staphylococcus aureus (ATCC 25953) and gram-negative bacteria viz., Micrococucus luteus (ATCC 9341), Entamoeba Coli (ATCC 11230) at 100 μg/ml concentration. The in vitro antimicrobial activity of the tested compounds was assessed by minimum inhibitory concentration (MIC) using the broth dilution method (National Committee for Clinical Laboratory Standards, 1982). Ciprofloxacin was used as standard drug for comparison and the data are presented in Table 3. The results of antibacterial screening (Table 3) reveal that compounds 7a–n displayed better activity and more active than the standard Ciprofloxacin. Compounds possessing 2-hydroxy 7b, 4-methyl 7g, and 4-nitro 7j substitutions on the phenyl ring showed remarkable growth inhibition. Both the electron donating as well as electron withdrawing groups present as substitutions on the benzene ring enhanced the antibacterial activity.

Table 3 Antibacterial activity of compounds (7a–n).
Compound Gram-positive Gram-negative
B. subtilis B. cereus S. aureus M. luteus E. coli
Minimum inhibitory concentrationa,b
7a 21 23 20 18 22
7b 18 20 16 17 19
7c 23 20 22 19 26
7e 20 26 18 24 20
7f 26 21 24 18 23
7g 17 20 15 11 13
7h 19 20 19 21 19
7i 18 26 21 23 23
7j 17 15 20 19 13
7k 20 21 22 26 18
7l 23 24 19 20 22
7m 21 22 26 23 24
7n 26 20 21 22 20
Ciprofloxacin 24 24 23 25 25
Negative control (Acetone) – No activity.
Concentration 100 μg/mL.

4.5

4.5 Antifungal activity

The target compounds 7a–n were also evaluated for their antifungal activity against Candida albicans (ATCC 10231) and Aspergillus niger (ATCC 16404) in acetone by the cup bioassay method (Margery Linday, 1962), using fluconazole as standard drug. The results are summarized in Table 4. The antifungal activity results (Table 4) indicate that compounds 7a–n are significantly toxic toward all the fungi under investigation. Compounds with the electron donating methoxy group on the phenyl ring 7h, 7i, and 7n are highly toxic toward the two fungi. However the degree of spore germination inhibition varied with the test compounds as well as with the fungi under investigation. The fungal activity of the compounds 7a–n has shown better activity, when compared with the standard drug Fluconazole.

Table 4 Antifungal activity of compounds (7a–n).
Compound Zone of inhibition in mma,b
C. albicans A.niger
7a 20 25
7b 18 23
7c 14 21
7d 20 18
7e 24 16
7f 21 10
7g 16 20
7h 28 21
7i 27 26
7j 20 23
7k 11 19
7l 25 15
7m 24 13
7n 30 24
Fluconazole 24 18
Negative control (acetone) – no activity.
Concentration 100 μg/mL.

5

5 Conclusion

In conclusion, we reported the multi-component (MCRs) synthesis of benzo[d]imidazolyl tetrahydropyridine carboxylates with potential biological activity using inexpensive and commercially available material in a one-pot reaction. This synthesis benefits from a simple method of purification and compliments the one-pot synthesis, making the technology practically easy to perform and facile. All the synthesized compounds 7a–n exhibited good anti-inflammatory, antioxidant and antimicrobial activities.

Acknowledgments

The authors are thankful to the chairman and principal of St. Peter’s Institute of Pharmaceutical Sciences, Vidhyanagar, Hanamkonda, India, for the facilities and to the Director, Indian Institute of Chemical Technology, Hyderabad, India, for the spectral facility.

References

  1. , , , . J. Heterocycl. Chem.. 2002;39:811-816.
  2. , . Statistical Methods in Medical Research. Oxford, London: Black well Scientific Publ; . 147
  3. , , . Pharmazie. 1982;37:551-553.
  4. , , , , , , , , , , , . Tetrahedron Lett.. 2003;44:1627-1629.
  5. , , , . Org. Lett.. 2003;5:435-438.
  6. , , , , , . Life Sci.. 1985;36:213-218.
  7. , , . , ed. Pyridine and Its Derivatives: A Supplement. Vol vol. 14. New York: Inter science Publishers; .
  8. , , , , , , , , , . Chem. Rev.. 1999;99:3329-3365.
  9. , , . J. Org. Lett.. 2005;7:239-242.
  10. , , . , , eds. Advances in Heterocyclic Chemistry. New York: Academic Press; . p. 2
  11. , , , , . Tetrahedron. 1995;51:10771-10794.
  12. , , , , , , . Eur. Pat. Appl. EP. 1987;5:22065.
  13. , , , , , . Arzneim. Forsch.. 1982;32:49-55.
  14. , . Acc. Chem. Res.. 2000;33:879-888.
  15. Kozo, A., Kazuniro, A., Masayuki, K., Yongzhe, Y., 2001. US. Patent. 6815455, 2001. Chem. Abstr, 134, 86247.
  16. Labaw, C. S., Webb, R. L., 1981. U.S. Patent. 4285878. Chem. Abstr. 1981. 95, 168837.
  17. , . Life Sci.. 1985;36:201-206.
  18. , , , , . Science. 1983;219:979-980.
  19. , , , , . Br. Res.. 1984;292:390-394.
  20. , , , , . Chem. Rev.. 2004;104:6085-6117.
  21. , . Practical Introduction to Microbiology. Spon Ltd., E & F.N; . 177
  22. , . Method for dilution antimicrobial susceptibility tests for bacteria, which grows aerobically. Villanova: Nat. Comm. Clini Lab Stands, Ltd.; . p. 2
  23. , , , , , . Bioorg. Med. Chem.. 1997;5:1543-1553.
  24. , , . Angew. Chem. Int. Ed.. 2005;44:1602-1634.
  25. , , , . Int. J. Biol. Chem.. 2010;4:19-26.
  26. , , , , . I. L. Farmaco. 2002;57:819-823.
  27. , , . J. Sulphur Chem.. 2012;3:363-372.
  28. , , . Indian J. Heterocycl. Chem.. 2012;21:229-232.
    [Google Scholar]
  29. , , . Het. Lett.. 2012;2:291-296.
  30. , , . Chem. Commun.. 2004;5:508-509.
  31. , , . Pharmaceutical Chemistry. New York: John Wiley & Sons; .
  32. , , , , , , . Eur. J. Med. Chem.. 2002;37:835-843.
  33. , , . Curr. Opin. Drug Discor. Dev.. 2005;8:723-740.
  34. , . Pure Appl. Chem.. 2001;73:187-191.
  35. , , , . Proc. Soc. Exp. Biol. Med. III. 1962;111:544-547.
  36. , . Chem. Rev.. 1951;48:397-541.
  37. , , , , , , , , , , , , , , , . J. Med. Chem.. 2001;44:3469-3487.
  38. , , , , . J. Comb. Chem.. 2005;7:147-169.
Show Sections